MX361299B - Metodo para activar celulas auxiliares. - Google Patents

Metodo para activar celulas auxiliares.

Info

Publication number
MX361299B
MX361299B MX2013003884A MX2013003884A MX361299B MX 361299 B MX361299 B MX 361299B MX 2013003884 A MX2013003884 A MX 2013003884A MX 2013003884 A MX2013003884 A MX 2013003884A MX 361299 B MX361299 B MX 361299B
Authority
MX
Mexico
Prior art keywords
molecule
hla
drb1
cell
helper
Prior art date
Application number
MX2013003884A
Other languages
English (en)
Other versions
MX2013003884A (es
Inventor
Yoshihiro Goto
Haruo Sugiyama
Shinji Sogo
Masayoshi Sato
Ryuki Kitamoto
Original Assignee
Otsuka Pharmaceutical Co Ltd Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd Star filed Critical Otsuka Pharmaceutical Co Ltd Star
Publication of MX2013003884A publication Critical patent/MX2013003884A/es
Publication of MX361299B publication Critical patent/MX361299B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

La presente invención se refiere a un método para activar las células T auxiliares, que comprende el paso de activar las células T auxiliares agregando un péptido WT1 a las células que presentan antígenos, en donde el péptido WT1 tiene la capacidad de unirse a cualquier moléculas MHC Clase II de una molécula HLA-DRB1* 0101, una molécula HLADRB1* 0401, una molécula HLADRB1* 0403, una molécula HLADRB1* 0406, una molécula HLA-DRB1* 0803, una molécula HLADRB1* 0901, una molécula HLA10 DRB1* 1101, una molécula HLADRB3* 0202, una molécula HLADRB4* 0101, una molécula HLA-DPB1 0201, o una molécula HLADPB1* 0301.
MX2013003884A 2010-10-05 2011-10-04 Metodo para activar celulas auxiliares. MX361299B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010225806 2010-10-05
PCT/JP2011/072874 WO2012046730A1 (ja) 2010-10-05 2011-10-04 ヘルパーｔ細胞の活性化方法

Publications (2)

Publication Number Publication Date
MX2013003884A MX2013003884A (es) 2013-07-05
MX361299B true MX361299B (es) 2018-11-30

Family

ID=45927725

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013003884A MX361299B (es) 2010-10-05 2011-10-04 Metodo para activar celulas auxiliares.
MX2018008436A MX2018008436A (es) 2010-10-05 2013-04-05 Metodo para activar celulas t auxiliares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018008436A MX2018008436A (es) 2010-10-05 2013-04-05 Metodo para activar celulas t auxiliares.

Country Status (20)

Country Link
US (2) US10654892B2 (es)
EP (1) EP2626418B8 (es)
JP (3) JP6134139B2 (es)
KR (3) KR102171794B1 (es)
CN (2) CN105802910A (es)
AR (1) AR083295A1 (es)
AU (1) AU2011313327B2 (es)
BR (1) BR112013008230A2 (es)
CA (1) CA2813557C (es)
CO (1) CO6710946A2 (es)
EA (1) EA037547B1 (es)
ES (1) ES2849187T3 (es)
IL (2) IL225536B (es)
MX (2) MX361299B (es)
MY (1) MY170306A (es)
NZ (2) NZ609460A (es)
SG (3) SG189287A1 (es)
TW (2) TW201623616A (es)
WO (1) WO2012046730A1 (es)
ZA (1) ZA201303056B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130062368A (ko) 2003-11-05 2013-06-12 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3834836A1 (en) 2006-04-10 2021-06-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and uses thereof
NZ599161A (en) 2007-02-27 2012-07-27 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
TW201623616A (zh) * 2010-10-05 2016-07-01 癌免疫研究所股份有限公司 用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物
EP2802347B1 (en) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN104797711B (zh) * 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
NZ708990A (en) * 2012-12-17 2020-03-27 Int Inst Cancer Immunology Inc Method for activating helper t cell
CN116789792A (zh) 2013-01-15 2023-09-22 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
AU2014244860B2 (en) 2013-03-29 2018-07-26 International Institute Of Cancer Immunology, Inc. WT1-antigen peptide conjugate vaccine
CN106029699B (zh) 2014-02-26 2019-07-19 泰来有限公司 Wt1抗原性多肽和含有该多肽的抗肿瘤剂
KR102588853B1 (ko) 2014-12-25 2023-10-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 T 세포 집단의 개변 방법
CN106565836B (zh) * 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
JP6994201B2 (ja) 2016-11-09 2022-02-21 国立大学法人大阪大学 Ｔ細胞集団の改変方法
US20200016255A1 (en) * 2016-11-30 2020-01-16 Sumitomo Dainippon Pharma Co., Ltd. Wt1 helper peptides and combinations of wt1 helper peptide and conjugate of cancer antigen peptides
WO2019131722A1 (ja) * 2017-12-27 2019-07-04 大日本住友製薬株式会社 Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
EP4043569A1 (en) * 2018-02-15 2022-08-17 National University Corporation Asahikawa Medical University Cancer antigen peptide

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CZ20011144A3 (cs) 1998-09-30 2002-06-12 Corixa Corporation Prostředky a způsoby pro WT1 specifickou imunoterapii
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
EP1261711A2 (en) 2000-02-22 2002-12-04 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
CA2440303C (en) 2001-03-22 2013-03-19 Haruo Sugiyama Wt1 modified peptide
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
CN1320923C (zh) 2001-06-29 2007-06-13 中外制药株式会社 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
WO2003028757A1 (fr) 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
EP1447092A4 (en) 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
CN101113163B (zh) 2002-06-12 2010-10-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
EP1550453B1 (en) 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
DE60329201D1 (de) 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
ATE444969T1 (de) 2003-01-15 2009-10-15 Int Inst Cancer Immunology Inc Dimerisiertes peptid
EP2338509B1 (en) 2003-06-27 2014-06-18 International Institute of Cancer Immunology, Inc. Method of selecting patients suitable for WT1 vaccine
KR20130062368A (ko) * 2003-11-05 2013-06-12 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드
PL1731605T3 (pl) 2004-03-31 2010-08-31 Int Inst Cancer Immunology Inc Nowotworowe peptydy antygenowe pochodzące z WT1
US7608769B2 (en) * 2004-05-12 2009-10-27 First Act, Inc. Packaged drum set
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
US7420880B2 (en) 2005-12-29 2008-09-02 Timex Group B.V. Multimode electronic device with calibrating/setting mechanism
SI1988163T1 (sl) 2006-02-22 2012-09-28 Int Inst Cancer Immunology Inc HLA-A*3303-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
EP3834836A1 (en) 2006-04-10 2021-06-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and uses thereof
NZ592510A (en) 2006-12-28 2012-11-30 Int Inst Cancer Immunology Inc HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
NZ599161A (en) * 2007-02-27 2012-07-27 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
EP3173480A3 (en) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
TW201623616A (zh) * 2010-10-05 2016-07-01 癌免疫研究所股份有限公司 用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物
NZ708990A (en) 2012-12-17 2020-03-27 Int Inst Cancer Immunology Inc Method for activating helper t cell

Also Published As

Publication number Publication date
JP6134139B2 (ja) 2017-05-24
NZ703560A (en) 2016-11-25
AU2011313327A1 (en) 2013-05-02
MX2018008436A (es) 2021-12-08
JP2018093870A (ja) 2018-06-21
AR083295A1 (es) 2013-02-13
EP2626418A4 (en) 2014-02-19
KR102171794B1 (ko) 2020-10-29
US20200354405A1 (en) 2020-11-12
CN105802910A (zh) 2016-07-27
SG10202108581TA (en) 2021-09-29
SG189287A1 (en) 2013-05-31
CA2813557A1 (en) 2012-04-12
TW201623616A (zh) 2016-07-01
BR112013008230A2 (pt) 2016-06-14
KR20190034359A (ko) 2019-04-01
US20130266958A1 (en) 2013-10-10
KR102079480B1 (ko) 2020-02-19
ZA201303056B (en) 2013-12-23
EP2626418B1 (en) 2020-12-09
EP2626418B8 (en) 2021-03-24
JPWO2012046730A1 (ja) 2014-02-24
MY170306A (en) 2019-07-17
TW201217525A (en) 2012-05-01
ES2849187T3 (es) 2021-08-16
EA201390509A1 (ru) 2013-08-30
JP2017006120A (ja) 2017-01-12
IL245440A0 (en) 2016-06-30
EP2626418A1 (en) 2013-08-14
MX2013003884A (es) 2013-07-05
CA2813557C (en) 2021-05-04
KR20140009168A (ko) 2014-01-22
IL225536A0 (en) 2013-06-27
NZ609460A (en) 2015-07-31
IL225536B (en) 2019-03-31
AU2011313327B2 (en) 2015-10-22
KR20200018738A (ko) 2020-02-19
WO2012046730A1 (ja) 2012-04-12
EA037547B1 (ru) 2021-04-12
US10654892B2 (en) 2020-05-19
TWI608099B (zh) 2017-12-11
CN103298928B (zh) 2016-04-20
JP6298101B2 (ja) 2018-03-20
SG10201508252PA (en) 2015-11-27
CO6710946A2 (es) 2013-07-15
CN103298928A (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
MX2018008436A (es) Metodo para activar celulas t auxiliares.
PH12015501361A1 (en) Method for activating helper t cell
CY1120471T1 (el) Αντισωματα κατα του cd70
MY164867A (en) Method for activation of helper t cell and composition for use in the method
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
MX2011000767A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
MY173793A (en) New pcr sequencing method and use thereof in hla genotyping
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MX2012007340A (es) Anticuerpos anti/her3 y usos de los mismos.
AU2013361107A8 (en) Human anti-tau antibodies
GB201020995D0 (en) Biological materials and uses thereof
MX345092B (es) Anticuerpos anti-tau humanos,.
EA201391059A1 (ru) Композиции для лечения рака и способы их применения
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
AU2012323781A8 (en) Antibodies to CD1d
WO2010057647A3 (en) Methods and compositions for the diagnosis and treatment of diabetes
EP2593548A4 (en) ANTIGEN E7 COMPOSITIONS OF HUMAN PAPILLOMAVIRUS AND USES THEREOF
CY1114823T1 (el) Φαινυλ-αλκυλ πιπεραζινες οι οποιες διαθετουν μια ρυθμιστικη δραστηριοτητα του τνf
MY170643A (en) Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
TH156195A (th) วิธีเพื่อกระตุ้นเฮลพ์เพอร์ t เซลล์
TH165802A (th) วิธีสำหรับการแอคทิเวต เฮลเปอร์ t เซลล์
TH165802B (th) วิธีสำหรับการแอคทิเวต เฮลเปอร์ t เซลล์

Legal Events

Date Code Title Description
FG Grant or registration